Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapyMatthew Holderfield, Mallika Singh, Elena S. Koltun et al.|Nature|2024Cited by 319
In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinomaMarie‐Julie Nokin, David Santamarı́a|Cell Reports Medicine|2024Cited by 20
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapyMallika Singh, David Wildes, Matthew Holderfield et al.|Research Square|2023Cited by 5